MedTrace Logo

Perennial Malaria Chemoprevention (PMC) Effect Study

NCT06155448 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2000

Last updated 2023-12-04

No results posted yet for this study

Summary

The Malaria Consortium Nigeria (MC) will coordinate a trial of PMC in Osun State, Nigeria with strategic support from the National Malaria Elimination Programme of the Government of Nigeria (NMEP) and financial support from the BMGF. The primary purpose of the study is to provide evidence of the impact of PMC on malaria burden and related clinical outcomes, and its operational feasibility for policy decision and the inclusion of PMC into upcoming programme and funding cycles for its National Malaria Control Strategic Plan. The objectives are:

1. To evaluate the impact of PMC in children aged 2-18 months on key child health outcomes including malaria burden, hospitalisations, and anaemia.
2. To describe indicators of operational feasibility of PMC by identification and measurement of key determinants of successful uptake and implementation of PMC.

Conditions

Interventions

OTHER

Perennial Malaria Chemoprevention effect

Assessing the effectiveness and feasibility of Perennial malaria chemoprevention delivery through EPI platform.

Sponsors & Collaborators

  • Nigerian Institute of Medical Research

    collaborator OTHER_GOV

  • London School of Hygiene and Tropical Medicine

    collaborator OTHER

  • Northwestern University

    collaborator OTHER

  • Malaria Consortium

    lead OTHER

Principal Investigators

  • James Tibenderana, PhD · Malaria Consortium

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
10 Weeks
Max Age
24 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-08-08
Primary Completion
2025-08-07
Completion
2026-12-31

Countries

  • Nigeria

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06155448 on ClinicalTrials.gov